17 Novermber 2014 - The fixed combination of canagliflozin with metformin (trade name: Vokanamet) has been approved since April 2014 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in a dossier assessment whether the new drug combination offers an added benefit over the appropriate comparator therapy. No such added benefit can be derived from the dossier, however, because the manufacturer did not present any suitable data for any of the possible subindications. 

IQWiG already came to the same conclusion in the assessment of canagliflozin as monotherapy and in various free combination therapies in June 2014.

For more details, got to: https://www.iqwig.de/en/press/press-releases/press-releases/type-2-diabetes-added-benefit-of-canagliflozin-plus-metformin-is-not-proven.6425.html